Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roman Politi

Neurology Marquette, MI Medical Doctor

NPI 1588656466 CMS profile 71832

580 W College Ave, Marquette, MI 49855

Open in the dashboard

General payments

$200,828

909 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roman Politi of Marquette, MI is reported in the CMS Open Payments database as having received $200,828 across 909 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,016 59
2024 General $37,065 130
2023 General $28,175 91
2022 General $16,506 144
2021 General $37,532 185
2020 General $14,663 122
2019 General $56,872 178

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roman Politi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Roman Politi were reported at $10,016. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Roman Politi Neurology median Middle half National median
2019 $56,872 $474 $118–$2,177 $163
2020 $14,663 $367 $82–$2,309 $114
2021 $37,532 $438 $104–$2,547 $132
2022 $16,506 $442 $103–$2,388 $149
2023 $28,175 $464 $119–$2,312 $160
2024 $37,065 $468 $119–$2,323 $164
2025 $10,016 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acorda Therapeutics, Inc $76,826 130 payments
  2. AbbVie, Inc. $39,159 75 payments
  3. ACADIA Pharmaceuticals Inc $23,801 69 payments
  4. Genzyme Corporation $13,609 30 payments
  5. Allergan Inc. $11,349 45 payments
  6. Biohaven Pharmaceuticals, Inc. $10,779 29 payments
  7. LivaNova USA, Inc. $5,895 25 payments
  8. E.R. Squibb & Sons, L.L.C. $4,298 5 payments
  9. Novartis Pharmaceuticals Corporation $3,180 62 payments
  10. EMD Serono, Inc. $1,370 37 payments
  11. Other $10,562 402 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $141,818 76 payments
  2. Travel and Lodging $28,902 117 payments
  3. Food and Beverage $20,212 706 payments
  4. Consulting Fee $9,450 5 payments
  5. Education $445 5 payments
Products named General payments · program years 2019–2025
  1. INBRIJA Parkinsons Disease $56,035 92 payments
  2. UBRELVY Neuroscience $36,208 44 payments
  3. NUPLAZID $23,577 57 payments
  4. INBRIJA Parkinson's Disease $20,505 32 payments
  5. QULIPTA $20,335 32 payments
  6. NURTEC ODT $11,365 34 payments
  7. AUBAGIO Multiple Sclerosis $10,309 15 payments
  8. UBRELVY Neuroscience $7,724 18 payments
  9. AUBAGIO Neurology $3,180 14 payments
  10. KESIMPTA $2,252 21 payments
  11. Other $18,507 602 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

4,480

Median for Neurology: 833

Drug cost

$1,500,843

Median for Neurology: $202,670

Branded share of claims

29.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Evrysdi Risdiplam Brand 17 $446,784
Tecfidera Dimethyl Fumarate Brand 16 $201,493
Nuplazid Pimavanserin Tartrate Brand 36 $197,009
Qulipta Atogepant Brand 67 $83,532
Nurtec Odt Rimegepant Sulfate Brand 57 $54,219
Glatopa Glatiramer Acetate Brand 15 $51,748
Briviact Brivaracetam Brand 33 $51,274
Ubrelvy Ubrogepant Brand 46 $48,706
Aptiom Eslicarbazepine Acetate Brand 22 $39,039
Emgality Pen Galcanezumab-Gnlm Brand 52 $38,594

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$127,681

Of which drugs: $70,315

Medicare patients

224

Average age 72

Services billed

15,063

129 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 50%
Depression 39%
Diabetes 25%
Ischemic heart disease 23%
Chronic kidney disease 19%
Alzheimer's or dementia 19%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 19 14,240 $70,118

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
$14,586 36 —
INBRIJA
$10,506 — —
UBRELVY
$5,009 46 —
QULIPTA
$2,719 67 —
BRIUMVI
$260 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

909 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record